BG
ABEO icon

Bollard Group’s Abeona Therapeutics ABEO Stock Holding History

Bollard Group’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-49,393
Closed -$281K – 267
2025
Q2 		$281K Buy
+49,393
New +$281K 0.01% 171

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Bollard Group's ABEO Position: Q3 2025 in Review

Bollard Group sold out of Abeona Therapeutics (ABEO) in Q3 2025, closing a stake of 49,393 shares — an estimated $281K sold.

Bollard Group first reported a position in ABEO in Q2 2025 and held it in 1 quarter. The position peaked at $281K in Q2 2025. 100 funds tracked by Wall St. Rank hold ABEO as of Q3 2025.

  • Bollard Group reported no remaining Abeona Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bollard Group sold 49,393 Abeona Therapeutics shares in Q3 2025, an estimated $281K.
  • Bollard Group first reported a position in Abeona Therapeutics in Q2 2025 and held it in 1 quarter.
  • Bollard Group's Abeona Therapeutics position peaked at $281K in Q2 2025.
  • 100 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2025.

Based on Bollard Group's 13F filing for Q3 2025, filed 14 Nov 2025.